Show simple item record

dc.contributor.authorPentheroudakis, Georgeen
dc.contributor.authorPavlidis, Nicholasen
dc.creatorPentheroudakis, Georgeen
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:54:29Z
dc.date.available2018-06-22T09:54:29Z
dc.date.issued2006
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42371
dc.description.abstractCancer of unknown primary site (CUP) ranks as the fourth most common cause of cancer deaths. Regression of the primary, early development of systemic metastases and resistance to therapy are hallmarks of this heterogeneous clinical entity. Targeted therapy offers promise for improvement of outcome of such patients, but it is currently hindered by lack of known molecular targets on which tumours are dependent for growth. In this review, we present the gene and protein profiling studies done on expression of oncogenes, tumour-suppressor genes and angiogenesis effectors and discuss the therapeutic potential of developed targeted agents. Existing data show occasional overexpression of Ras, BCL2 oncoproteins, absence of active EGFR/c-KIT/PDGFR signalling, uncommon presence of tumour-suppressor gene mutations and highly active angiogenesis in CUP. High-throughput multi-gene, multi-protein platforms offer promise for unravelling the complex molecular pathophysiology of CUP, for identification of targets suitable for modulation and ultimately hope for abrogation of its aggressive natural history. © 2006 Elsevier Ltd. All rights reserved.en
dc.language.isoengen
dc.sourceCancer treatment reviewsen
dc.subjectAntineoplastic agenten
dc.subjectAntineoplastic agentsen
dc.subjectCisplatinen
dc.subjectHumanen
dc.subjectNeoplasmsen
dc.subjectHumansen
dc.subjectBreast canceren
dc.subjectDrug responseen
dc.subjectClinical trialen
dc.subjectAntineoplastic activityen
dc.subjectTreatment outcomeen
dc.subjectReviewen
dc.subjectErlotiniben
dc.subjectMetastasisen
dc.subjectNeoplasticen
dc.subjectCancer mortalityen
dc.subjectImatiniben
dc.subjectUnindexed drugen
dc.subjectColorectal canceren
dc.subjectLapatiniben
dc.subjectTrastuzumaben
dc.subjectGenetic polymorphismen
dc.subjectProtein bcl 2en
dc.subjectProtein p53en
dc.subjectGene expression regulationen
dc.subjectCarcinogenesisen
dc.subjectCanceren
dc.subjectGelatinase ben
dc.subjectSignal transductionen
dc.subjectTumor vascularizationen
dc.subjectCancer therapyen
dc.subjectBevacizumaben
dc.subjectGefitiniben
dc.subjectSorafeniben
dc.subjectSunitiniben
dc.subjectDrug treatment failureen
dc.subjectUnknown primaryen
dc.subjectPathophysiologyen
dc.subjectUnknown primaryen
dc.subjectGene expression profilingen
dc.subjectDrug targetingen
dc.subjectGene mutationen
dc.subjectPlatelet derived growth factor receptoren
dc.subjectStem cell factor receptoren
dc.subjectHead and neck canceren
dc.subjectCetuximaben
dc.subjectVandetaniben
dc.subjectCancer resistanceen
dc.subjectEpidermal growth factor receptor 2en
dc.subjectTissue inhibitor of metalloproteinase 1en
dc.subjectCd34 antigenen
dc.subjectThrombospondin 1en
dc.subjectRas proteinen
dc.subjectOncogenesen
dc.subjectAdvexinen
dc.subjectAntiangiogenic activityen
dc.subjectCyclooxygenase 2en
dc.subjectLonafarniben
dc.subjectMalignant transformationen
dc.subjectOblimersenen
dc.subjectOnyx 015en
dc.subjectTargeted therapyen
dc.subjectThalidomideen
dc.subjectTipifarniben
dc.titlePerspectives for targeted therapies in cancer of unknown primary siteen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ctrv.2006.08.004
dc.description.volume32
dc.description.issue8
dc.description.startingpage637
dc.description.endingpage644
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record